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Abstract: There are three critical pathways for the pathogenesis and progression of pulmonary arterial
hypertension (PAH): the prostacyclin (prostaglandin I2) (PGI2), nitric oxide (NO), and endothelin
pathways. The current approved drugs targeting these three pathways, including prostacyclin (PGI2),
phosphodiesterase type-5 (PDE5) inhibitors, and endothelin receptor antagonists (ERAs), have been
shown to be effective, however, PAH remains a severe clinical condition and the long-term survival
of patients with PAH is still suboptimal. The full therapeutic abilities of available drugs are reduced
by medication, patient non-compliance, and side effects. Nanoparticles are expected to address
these problems by providing a novel drug delivery approach for the treatment of PAH. Drug-loaded
nanoparticles for local delivery can optimize the efficacy and minimize the adverse effects of drugs.
Prostacyclin (PGI2) analogue, PDE5 inhibitors, ERA, pitavastatin, imatinib, rapamycin, fasudil, and
oligonucleotides-loaded nanoparticles have been reported to be effective in animal PAH models and
in vitro studies. However, the efficacy and safety of nanoparticle mediated-drug delivery systems for
PAH treatment in humans are unknown and further clinical studies are required to clarify these points.
Keywords: pulmonary arterial hypertension; prostaglandin I2; nitric oxide; endothelin
1. Introduction
Pulmonary arterial hypertension (PAH) is a progressive disease caused by vasoconstriction and
remodeling of the pulmonary vasculature [1–3]. Recent development of PAH-targeted drugs has
resulted in improvement of prognosis and quality of life in patients with PAH [4,5]. However, long-term
survival of patients with PAH is still suboptimal. Therefore, new treatment is thought to be needed.
2. Medical Treatment of Pulmonary Arterial Hypertension (PAH)
Modern development of drugs for PAH focus on three pathways, namely the prostacyclin
(prostaglandin I2) (PGI2), nitric oxide (NO), and endothelin pathways [4,6]. Impaired production of
vasodilators such as PGI2 and NO, along with over-expression of vasoconstrictors such as endothelin-1
are critical for the pathogenesis and progression of PAH. Drugs targeting the three pathways,
including prostacyclin (PGI2), endothelin receptor antagonists (ERAs), phosphodiesterase type-5
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(PDE5) inhibitors, and a soluble guanylate cyclase (sGC) stimulator, are currently available and have
been shown to be effective (Figure 1) [4,7–11].
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 2 of 12 
 
including prostacyclin (PGI2), endothelin receptor antagonists (ERAs), phosphodiesterase type-5 
(PDE5) inhibitors, and a soluble guanylate cyclase (sGC) stimulator, are currently available and have 
been shown to be effective (Figure 1) [4,7–11]. 
Figure 1. Drugs targeting the three pathways involved in the pathogenesis of pulmonary arterial 
hypertension. eNOS, endothelial nitric oxide synthase; PGI2, prostaglandin I2; NO, nitric oxide; ET-1, 
endothelin-1; IP, prostaglandin I2 receptor; ETA, endothelin type A receptor; ETB, endothelin type B 
receptor; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; GTP guanosine 
triphosphate; cGMP, cyclic guanosine monophosphate; PDE5, phosphodiesterase type 5. 
2.1. Prostacyclin (PGI2) 
Prostacyclin (PGI2) is released by endothelial cells and activates adenylate cyclase via the 
prostaglandin I2 receptor (IP) in pulmonary artery smooth muscle cells (PASMCs). Activated 
adenylate cyclase catalyzes the conversion of adenosine triphosphate (ATP) to 3’5’-cyclic AMP 
(cAMP), which activates protein kinase A (PKA). PKA goes on to promote the phosphorylation of 
myosin light chain kinase, which leads to smooth muscle relaxation and vasodilation. 
Prostacyclin, also known as epoprostenol; synthetic prostacyclin analogues including 
treprostinil, iloprost, and beraprost, and a selective prostacyclin receptor (IP receptor) agonist, selexipag, 
are used for the treatment of PAH. The efficacy of continuous intravenous epoprostenol therapy has 
been tested in three unblinded randomized clinical trials (RCTs) in patients with idiopathic PAH 
(IPAH) [12,13] and in patients with pulmonary hypertension (PH) owing to the scleroderma 
spectrum of disease, WHO-functional class (WHO-FC) III or IV despite optical medical therapy [14]. 
In RCTs, epoprostenol treatment improves symptoms, exercise capacity, and hemodynamics, and 
reduces mortality of patients with IPAH [9,13]. Selexipag, an oral IP receptor agonist, significantly 
reduced a composite of death from any cause or a complication related to PAH (GRIPHON trial) [15]. 
2.2. Phosphodiesterase Type 5 (PDE5) Inhibitors and Soluble Guanylate Cyclase (sGC) Stimulator 
Nitric oxide (NO) released from vascular endothelium activates the enzyme guanylate cyclase, 
which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth 
muscle relaxation in pulmonary arteries. The critical role of the NO-sGC-cGMP pathway in 
regulating pulmonary vascular tone is demonstrated by the dysregulation of NO production, sGC 
activity, and cGMP degradation in PH. 
Figure 1. Drugs targeting the three pathways involved in the pathogenesis of pulmonary arterial
hypertension. eNOS, endothelial nitric oxide synthase; PGI2, prostaglandin I2; NO, nitric oxide; ET-1,
endothelin-1; IP, prostaglandin I2 receptor; ETA, endothelin type A receptor; ETB, endothelin type
B receptor; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; GTP guanosine
triphosphate; cGMP, cyclic guanosine monophosphate; PDE5, phosphodiesterase type 5.
2.1. Prostacyclin (PGI2)
Prostacyclin (PGI2) is released by endothelial cells and activates adenylate cyclase via the
prostaglandin I2 receptor (IP) in pulmonary artery smooth muscle cells (PASMCs). Activated adenylate
cyclase catalyzes the conversion of adenosine triphosphate (ATP) to 3’5’-cyclic AMP (cAMP), which
activates protein kinase A (PKA). PKA goes on to promote the phosphorylation of myosin light chain
kinase, which leads to smooth muscle relaxation and vasodilation.
Prostacyclin, also known as epoprostenol; synthetic prostacyclin analogues including treprostinil,
iloprost, and beraprost, and a selective prostacyclin receptor (IP receptor) agonist, selexipag, are used
for the treatment of PAH. The efficacy of continuous intravenous epoprostenol therapy has been tested
in three unblinded randomized clinical trials (RCTs) in patients with idiopathic PAH (IPAH) [12,13]
and in patients with pulmonary hypertension (PH) owing to the scleroderma spectrum of disease,
WHO-functional class (WHO-FC) III or IV despite optical medical therapy [14]. In RCTs, epoprostenol
treatment improves symptoms, exercise capacity, and hemodynamics, and reduces mortality of patients
with IPAH [9,13]. Selexipag, an oral IP receptor agonist, significantly reduced a composite of death
from any cause or a complication related to PAH (GRIPHON trial) [15].
2.2. Phosphodiesterase Type 5 (PDE5) Inhibitors and Soluble Guanylate Cyclase (sGC) Stimulator
Nitric oxide (NO) released from vascular endothelium activates the enzyme guanylate cyclase,
which results in increased levels of cyclic guanosine monophosphate (cGMP), leading to smooth
muscle relaxation in pulmonary arteries. The critical role of the NO-sGC-cGMP pathway in regulating
pulmonary vascular tone is demonstrated by the dysregulation of NO production, sGC activity, and
cGMP degradation in PH.
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PDE5 inhibitors inhibit the degradation of cGMP by PDE5. Sildenafil and tadalafil have been
used for the treatment of PAH. Riociguat is a pharmacological agent that directly stimulates sGC,
both independently of NO and in synergy with NO. Riociguat treats two forms of PH: chronic
thromboembolic pulmonary hypertension (CTEPH) and PAH.
2.3. Endothelin Receptor Antagonists (ERAs)
Endothelin type A receptor (ETA) and type B receptor (ETB) are G protein-coupled receptors
whose activation results in elevation of intracellular-free calcium. Endothelin-1 (ET-1) abluminally
released from vascular endothelium causes the underlying smooth muscle to contract, mainly via
ETA. ERAs are drugs that block endothelin receptors. Selective ETA receptor antagonists, ambrisentan,
and dual antagonists that affect ETA and ETB, including bosentan and macitentan, are used for the
treatment of PAH. In an RCT (SERAPHIN trial) adopting clinical aggravation as the composite primary
endpoint, which consists of a first event related to PAH or death from any cause, the macitentan 10 mg
treatment group showed significant improvement compared with the placebo group [16].
2.4. Combination Therapy
Recently, most experts in PH have empirically used a combination of PAH-targeted drugs for
treating patients [5,17,18]. The Japan PH registry showed that initial upfront combination therapy
was associated with improvement in hemodynamic status [5]. The AMBITION study showed that
using the upfront combination therapy with ambrisentan and tadalafil reduced the risk of the primary
endpoint of the first event of clinical failure (a composite of death, hospitalization for worsening
pulmonary arterial hypertension, disease progression, or unsatisfactory long-term clinical response) by
50% compared with each individual treatment [19].
2.5. Current Status and Future Perspectives
As noted above, current approved drugs that target the three described pathways have been
shown to be effective. However, PAH remains a severe clinical condition despite the publication of
41 RCTs. Many researchers are working on finding novel therapeutic targets and potential drugs for
PAH [20,21].
Furthermore, the full therapeutic potential of the drugs targeting the three pathways is reduced by
medication, patient non-compliance, and side effects, meaning that the long-term survival of patients
with PAH remains suboptimal. To address these problems, several novel therapeutic strategies for
treating PAH, such as nanoparticle-mediated drug delivery systems (nano-DDS), have been proposed.
3. Nanoparticle-Mediated Drug Delivery Systems (Nano-DDS)
Nanoparticles (NPs) have been used in numerous novel delivery systems for the transport of
drugs to target organs [22–25]. NPs are taken up by the target organ because of their small size, which
allows them to permeate into tissue and be retained. Drug release from NPs can be controlled by the
NP composition. Thus, drug-loaded NPs for local delivery can optimize the efficacy and minimize the
side effects of drugs. All drugs have potential toxicity that may limit their safe dose and thereby their
therapeutic efficacy. The use of a nano-DDS can enhance the efficacy and safety of therapeutic agents,
and overcome drawbacks such as toxicity, low water solubility, and poor bioavailability [23].
Nano-DDS can be composed of a variety of materials and structures, including micelles,
liposomes, dendrimers, and polymers [23,25]. Polymeric nanospheres are formed by the assembly
of macromolecular polymers and can contain hydrophilic and hydrophobic therapeutic agents.
Two polymers, polylactide (PLA) and poly (lactide-co-glycolic acid) (PLGA), are used for the synthesis
of FDA-approved polymeric biodegradable nano-DDS (Figure 2) [23].
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Figure 2. Chemical structure of poly (lactide-co-glycolic acid) (PLGA) and a schematic representation
of a polymer nanoparticle. x and y represent the number of each unit in PLGA.
4. Nano-DDS for PAH Treatment
Treatment of P with vasodilators such as prostacyclin (PGI2), ERAs, PDE5 inhibitors, and
an sGC stimulator has been effective [4,7–11], however PAH is still a fatal disorder in some patients.
Intravenous administration of prostacyclin or systemic administration of imatinib causes several
adverse events and complications, therefore several novel therapeutic strategies for PAH, including
nano-DDS, have been proposed [24–26]. Nano-DDS for lung treatment could optimize the efficacy and
minimize the side effects of drugs.
Prostacyclin (PGI2) analogue [27–30], PDE5 inhibitors [31,32], ERA [33], oligonucleotides [34,35],
pitavastatin [36,37], imatinib [38], rapamycin [39], and fasudil [40]-loaded NPs have been reported to
be effective in animal PAH models and in vitro studies (Table 1). All of the data in the studies were
obtained in animal models of PAH or in vitro studies and have not yet been translated to human trials.
The efficacy and safety of nano-DDS for PAH in humans are unknown and further studies are needed
to clarify these issues.
Table 1. Nanoparticle-mediated drug delivery systems for PAH treatment.
Drug Delivery System Animal Model Route of Admin. Refs
Prostacyclin analogues
Beraprost Polymer (PLA and PEG-PLA) MCT-induced rat model Intravenous [27]
Beraprost Polymer (PLA and PEG-PLA) Hypoxia mouse model Intravenous [27]
Beraprost Polymer (PLGA) MCT-induced rat el Intratracheal [28]
Beraprost Polymer (PLGA) Sugen/hypoxia rat model Intratracheal [28]
Treprostinil Lipid nanoparticle Hypoxia rat model Inhalation [29]
Iloprost Liposome Isolated PA of mice [30]
PDE5 inhibitors
Sildenafil GlcA-modified liposome MCT-induced rat model Intravenous [31]
Tadalafil Polymer (PLGA) In vitro study [32]
ERA
Bosentan Polymer (PCL) In vitro study [33]
Others
Pitavastatin Polymer (PLGA) MCT-induced rat model Intratracheal [36]
Pitavastatin Polymer (PLGA) MCT-induced rat model Intravenous [37]
Imati ib P r (PLGA) MCT-induced rat model Intratracheal [38]
Rapamycin Polymer (PEG-PCL) MCT-induced rat model Intravenous [39]
Fasudil Liposome MCT-induced rat model Inhalation [40]
Oligonucleotides
NF-kB decoy Polymer (PEG-PLGA) MCT-induced rat model Intratracheal [34]
AntimiRNA-145 Liposome Sugen/hypoxia rat model Intravenous [35]
ERA, endothelin receptor antagonist; GlcA, glucuronic acid; MCT, monocrotaline; NF-kB, nuclear factor kappaB; PA,
pulmonary artery; PAH, pulmonary arterial hypertension; PCL, poly(ε-caprolactone); PDE5, phosphodiesterase
type-5; PEG-PCL, poly-(ethyleneglycol)-block-poly(ε-caprolactone); PEG-PLA, poly-(ethyleneglycol)-block-PLA;
PEG-PLGA, poly-(ethyleneglycol)-block- L A; PLA, poly(lactide) homopolymer; PLGA, polylactid -glycolide.
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4.1. Prostacyclin (PGI2) Analogue-Loaded Nanoparticles (NPs)
The production of endogenous prostacyclin (PGI2) is suppressed in pulmonary arteries of patients
with PAH. PGI2 synthase expression has been reported to be reduced in lung tissues from patients
with severe pulmonary hypertension (PH) [41]. Prostacyclin replacement therapy by infusion of
epoprostenol sodium, a prostacyclin (PGI2), is one of the best available treatments for severe PAH.
In RCTs, continuous intravenous epoprostenol therapy improves symptoms, exercise capacity, and
hemodynamics, and reduces mortality in patients with IPAH. We reported that high-dose epoprostenol
therapy (>40 ng/kg/min) resulted in marked hemodynamic improvement in patients with PAH [7,8,42].
Compared with the baseline state, high-dose epoprostenol therapy reduced mean pulmonary arterial
pressure (mPAP) by 30% and pulmonary vascular resistance (PVR) by 68%, and increased cardiac
index by 89% and SvO2 by 19% [7].
However, there are several adverse events and complications such as headache, hypotension, and
catheter-related infection in intravenous prostacyclin replacement therapy. Systemic administration
of prostacyclin can induce headache, flushing, and in some cases, severe hypotension at the start of
therapy. One of the most serious complications is catheter-related infections. These limitations could
potentially be resolved by the development of an alternative system to target prostacyclin delivery to
the pulmonary vasculature without using a central venous catheter.
Beraprost-loaded NPs: Nano-DDS using prostacyclin-loaded NPs for lung delivery might optimize
the efficacy and minimize the side effects of drugs. Therefore, we developed PLGA-NPs loaded
with beraprost, a prostacyclin analogue (beraprost-NPs) and investigated the efficacy and safety of
intratracheal administration of beraprost-NPs in Sugen-hypoxia-normoxia and monocrotaline (MCT)
rat models of PAH [28]. Single intratracheal administration of beraprost-NPs significantly reduced
right ventricular pressure, right ventricular hypertrophy, and pulmonary artery muscularization in
both rat models. Furthermore, beraprost-NPs significantly improved the survival rate in the MCT
rat model.
Intravenous administration (once per week) of poly(lactide) (PLA)-NPs loaded with beraprost
also prevent pulmonary arterial remodeling and right ventricular hypertrophy in MCT-induced rat
PAH model and hypoxia-induced mouse PAH model [27].
Treprostinil-loaded NPs: Trepostinil was also chemically modified to be an alkyl prodrug (TPD)
which was then packaged into a lipid nanoparticle (LNP) carrier. The TPD-LNP demonstrated
approximately lower treprostinil plasma concentration compared to inhaled treprostinil solution
while maintaining an extended vasodilatory effect in a rat model of hypoxia-induced pulmonary
vasoconstriction [29].
Iloprost-loaded NPs: Jain et al. synthesized liposomal nanoparticles tailored for the prostacyclin
analogue iloprost. Iloprost-NPs exhibited significantly enhanced vasodilation of isolated tertiary
pulmonary arteries in mice [30].
4.2. PDE5 Inhibitor-Loaded NPs
Sildenafil-loaded NPs: Sildenafil, a PDE5 inhibitor, exhibits the preventative effects of pulmonary
artery remodeling, however, conventional sildenafil has shown limited treatment efficacy owing to
its poor accumulation in pulmonary arteries. Li et al. reported that glucuronic acid (GlcA)-modified
liposomes with encapsulated sildenafil improved the delivery of sildenafil to aberrant over-proliferative
PASMCs by targeting glucose transport-1 (GLUT-1) and inhibited the remodeling of pulmonary arteries
in MCT-induced PH model rats [31].
Tadalafil-loaded NPs: Dry powder inhaler containing tadalafil-loaded PLGA NPs are
developed [32].
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4.3. ERA-Loaded NPs
Bosetntan-loaded NPs: Bosentan monohydrate-loaded ε-polycaprolactone (PLC) NPs are made
by electrospraying technique [33].
4.4. Others
Pitavastatin-loaded NPs: 3-Hydroxy-3-methylglutanyl coenzyme A (HMG-CoA) reductase
inhibitors (statins) are well-tolerated drugs, which are widely used for lowering serum low-density
lipoprotein cholesterol levels. Statins have pleiotropic effects, including improvement of endothelial
cell functions, inhibition of vascular smooth muscle cell growth, and anti-inflammatory effects [43,44].
Simvastatin, an HMG-CoA reductase inhibitor, significantly inhibited PDGF-induced cell proliferation
and migration of PASMCs from patients with idiopathic PAH [45]. In addition, simvastatin has
been shown to attenuate pulmonary vascular remodeling by increasing vascular SMCs, and improve
prognosis in rats with MCT-induced PH [46,47].
Pitavastatin, a statin, also has inhibitory effects on proliferation of PASMCs in vitro. Intratracheal
administration of PLGA-NPs loaded with pitavastatin (pitavastatin-NPs) attenuated the development
of MCT-induced rat PAH model [36]. Furthermore, a single intratracheal treatment with pitavastatin-NP
three weeks after MCT injection induced regression of PAH and improved the survival rate [36].
A phase I investigator-initiated clinical trial to test the safety, tolerability, and pharmacokinetics
of PLGA nanoparticle-mediated delivery of pitavastatin (NK-104-NP) has been completed
(UMIN000014940 and UMIN000019189) [48]. The results showed that the pitavastatin-loaded NPs
(NK-104-NP) exhibited dose-dependent pharmacokinetics and were well tolerated with no significant
AEs in healthy volunteers. Now phase II clinical trial is conducted (jRCT2031180075).
5. Future Challenges and Possible Nanomedicine-Based DDS Solutions
The future challenge is to synthesize and develop novel nanomedicine-based DDS for the
treatment of PAH that specifically target the pulmonary vascular cells, without exhibiting any toxicity
in other cells.
5.1. Targeting
In nanomedicine-based DDS for the treatment of cancer, NPs can target leaky tumor vasculature
through the enhanced permeability and retention (EPR) effect; however, the non-specificity towards
healthy cells and tissues is still high. To overcome this non-specific toxicity of NPs toward healthy
cells, several targeting agents have been used to enhance the tumor specific uptake and activity of
NPs (active targeting) [49]. Because αvβ3 integrin, a cell surface receptor, is dramatically upregulated
during neovascularization in the case of most cancers, targeting of integrin receptors by either αvβ3
integrin antibody or anti-angiogenic peptides (RGD/NGR), showed some exciting therapeutic results.
In PAH, there is an inhomogeneous distribution of vascular remodeling or cell viability conditions
in small pulmonary arteries. Therefore, patients with intractable PAH require cell-specific or vascular
compartment-specific therapies. Li et al. reported efficacious targeted delivery of sildenafil to PASMCs
with glucuronic acid (GlcA)-modified liposomes in an MCT-induced PH model in rats [31]. They first
demonstrated the overexpression of GLUT-1, a glucose transporter, on PASMCs in an MCT-induced
PH rat model. The overexpressed GLUT-1 provided a potential target for GlcA-modified liposomes.
5.2. Risk Assessment Strategy for Novel Nanomaterials
Establishing a risk assessment strategy for novel nanomaterials is important to reduce the number
of animal experiments. Conventional risk assessment techniques for chemical agents such as the
category approach, read-across, and quantitative structure–activity relationship (QSAR) models may
be useful [50,51].
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5.3. Novel Therapeutic Targets and Potential Drugs for PAH
In addition to traditional therapy, emerging pre-clinical data and clinical trials suggest novel
therapeutic targets and potential drugs for PAH (Table 2) [20,21]. Among those potential drugs,
imatinib and fasudil-loaded NPs have been reported [38,40]. NPs are expected to provide novel
delivery systems for the administration of potential drugs.
Table 2. Novel pathways, therapeutic targets, and potential drugs for PAH.
Pathways Therapeutic Targets Potential Drugs
Growth factor PDGF, EGF, FGF and VEGF tyrosine kinase inhibitors
Imatinib [52]
Inflammation IL-6 tocilizumab [53]
RAGE RAGE aptamer, AS-1 [54]
Nrf2 and NFkB bardoxolone methyl [21]
BMPR-II BMPR2 and sma-9 tacrolimus [55]
ataluren [56]
Metabolic modulators glucose oxidation dichloroacetate [57]
Neurohormonal activation sympathetic nerve system β-blockers [58]
DNA damage BRCA1 and PARP olaparib [21]
Epigenetic modification HDAC6 tubastatin A [59]
Vasoactive mediators 5HT 5HT-receptor antagonists [60]
rho A/ROCK fasudil [61]
adrenomedullin adrenomedullin [62]
Apelin apelin [63]
PDGF, platelet-derived growth factor; EGF, epidermal growth factor; FGF, fibroblast growth factor; VEGF, vascular
endothelial growth factor; IL, interleukin; RAGE, receptor for advanced glycation end products; BMPR, bone
morphogenetic protein receptor; BRCA1, breast cancer susceptibility gene I; PARP, Poly(ADP-ribose) polymerase 1;
HT, hydroxytryptamine; ROCK, rho-kinase.
6. Summary
In this review, we summarized current treatment strategies by drugs targeting the three pathways
and nano-DDS for PAH. Drug-loaded NPs for local delivery may optimize the efficacy and minimize
the side effects of drugs targeting the three pathways and other potential drugs. However, the efficacy
and safety of nano-drug delivery systems for PAH in humans are unknown. Further clinical studies
are needed to clarify these points.
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Abbreviations
ET-1 Endothelin-1
ETA endothelin type A receptor
ETB endothelin type B receptor
ERA endothelin receptor antagonists
FITC fluorescein isothiocyanate
GlcA glucuronic acid
GLUT-1 glucose transport-1
HMG-CoA 3-Hydroxy-3-methylglutanyl coenzyme A
IPAH idiopathic pulmonary arterial hypertension
MCT monocrotaline
mPAP mean pulmonary arterial pressure
nano-DDS nanoparticle-mediated drug delivery systems
NPs nanoparticles
PAH pulmonary arterial hypertension
PASMCs pulmonary artery smooth muscle cells
PDE5 phosphodiesterase type-5
PDGF platelet-derived growth factor
PEG poly-(ethyleneglycol)-block
PGI2 prostaglandin I2
PH pulmonary hypertension
PLA poly(lactide)
PLGA poly(lactide-co-glycolic acid)
PVR pulmonary vascular resistance
RCTs randomized clinical trials
sGC soluble guanylate cyclase
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